ADMA Biologics Files 8-K for Amendments and Exhibits

TL;DR

ADMA filed an 8-K for corporate updates and financials - no major news yet.

AI Summary

On June 27, 2024, ADMA Biologics, Inc. filed an 8-K report to disclose information regarding amendments to its articles of incorporation or bylaws and financial statements and exhibits. The filing does not contain specific financial figures or details about the amendments.

Why It Matters

This filing indicates updates to ADMA Biologics' corporate structure or financial reporting, which could be relevant for investors monitoring the company's governance and financial health.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose significant new risks or material adverse events.

Key Players & Entities

• ADMA BIOLOGICS, INC. (company) — Registrant
• June 27, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-36728 (identifier) — Commission File Number
• 56-2590442 (identifier) — IRS Employer Identification No.
• 465 State Route 17, Ramsey, New Jersey 07446 (address) — Address of principal executive offices
• R&R ACQUISITION VI, INC (company) — Former company name

FAQ

Filing Documents

• ef20031848_8k.htm (8-K) — 31KB
• ef20031848_ex3-1.htm (EX-3.1) — 202KB
• 0001140361-24-031778.txt ( ) — 404KB
• adma-20240627.xsd (EX-101.SCH) — 4KB
• adma-20240627_lab.xml (EX-101.LAB) — 22KB
• adma-20240627_pre.xml (EX-101.PRE) — 16KB
• ef20031848_8k_htm.xml (XML) — 4KB

03

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 27, 2024, the Board of Directors (the "Board") of ADMA Biologics, Inc. (the "Company") approved the Second Amended and Restated Bylaws of the Company (the "Second Amended and Restated Bylaws"), which became effective immediately. The Board adopted certain clarifying amendments and other updates, which, among other items, made the following changes: Article IV, Section 6(b) of the Second Amended and Restated Bylaws reduces the threshold of the holders of the voting power of all then outstanding shares of capital stock of the Company entitled to vote generally at an election of directors required to remove a director with cause (subject to any limitation imposed by law) from sixty-six and two-thirds percent (66 2/3%) of such holders to a majority of such holders; and The Second Amended and Restated Bylaws add Article XV, which requires, among other things, that (i) certain proceedings be exclusively brought in the Court of Chancery of the State of Delaware, or other courts of competent jurisdiction within the State of Delaware or the U.S. District Court for the District of Delaware, subject to such court having personal jurisdiction over the named defendants, and (ii) unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States be the exclusive forum for the resolution of any complaint asserting a cause of action against the Company or its officers and directors arising under the Securities Act of 1933, as amended. The foregoing description of the Second Amended and Restated Bylaws does not purport to be complete and is qualified entirely by reference to the full text of the Second Amended and Restated Bylaws, which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.

01

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 3.1 Second Amended and Restated Bylaws of ADMA Biologics, Inc. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. June 28, 2024 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President, Chief Executive Officer and Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR